Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Restore CFTR FunctionCompleted with results Location: USA

    SNO1: Study of N6022 in people with cystic fibrosis , protocol number Nivalis N30 N6022-1CF1-04

    This study tested the safety, tolerability of N6022 and its effects on CFTR biomarkers in people with CF.

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      10

    • Length of Participation:

      6 weeks

    Contact us about this clinical Trial >
  • Nutritional-GICompleted with results Location: USA

    Study of in-line digestive enzyme cartridge (Relizorb) in people with CF who are currently receiving enterel tube feedings , protocol number Alcresta 0000497

    This study took place at multiple care centres across the US. It looked at the safety and effectiveness of Relizorb, a new tube feeding in-line digestive enzyme cartridge. This cartridge is used with tube feedings to deliver digestive enzymes.

    • Age:

      4 Years to 82 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      Less than 100%

    • Number of Visits:

      4

    • Length of Participation:

      27 days

    Contact us about this clinical Trial >
  • Anti-InfectiveCompleted with results Location: USA

    Arikace for Nontuberculous Mycobacteria (NTM) , protocol number Insmed 112

    The purpose of this study was to determine whether Arikace is effective in treating recalcitrant nontuberculous mycobacterial lung disease. The safety and tolerability of Arikace in this patient population was also assessed.

    • Age:

      12 Years to 75 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      0

    • Length of Participation:

      12 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: USA

    SNO4: Study of N91115 in people with cystic fibrosis ages 18 and older with two copies of F508del-CFTR mutation. , protocol number Nivalis N91115-2CF-03

    This study is taking place at multiple care centers across the U.S. It will look at the safety of the drug N91115 as well as how the body processes the drug, in people with CF.

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      8

    • Length of Participation:

      6 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: USA

    Phase 2 study of riociguat in adults with CF , protocol number Bayer 63-2521/17020

    This study is taking place at multiple care centers across the U.S. It will look at the safety, tolerability and effectiveness of the oral drug riociguat and will use a placebo control.

    • Age:

      18 Years and Older

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      60 to 90%

    • Number of Visits:

      9

    • Length of Participation:

      28 days

    Contact us about this clinical Trial >
  • Nutritional-GIClosed to enrollment Location: USA

    ASSURE: Study of Relizorb in people with CF who receive enteral tube feeding , protocol number Alcresta 0000498

    This open label study is taking place at multiple care centres across the US. It will look at the safety, tolerability and effectiveness of Relizorb, a new digestive enzyme cartridge for people using enteral tube feedings.

    • Age:

      4 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      Less than 100%

    • Number of Visits:

      5

    • Length of Participation:

      4 months

    Contact us about this clinical Trial >
  • Nutritional-GIClosed to enrollment Location: USA

    SOLUTION: Study of Liprotamase in people with CF , protocol number Anthera AN-EP13331

    This study is taking place at multiple care centres across the US. It will look at the safety and effectiveness of the drug Liprotamase in people with CF who are currently taking digestive enzymes.

    • Age:

      7 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      30% or greater

    • Number of Visits:

      10

    • Length of Participation:

      28 weeks

    Contact us about this clinical Trial >
  • Nutritional-GIEnrolling Location: USA

    SIMPLICITY: Phase 3 study of liprotamase in people with CF-related pancreatic insufficiency , protocol number Anthera AN-EP13332

    This two-part study is taking place at multiple care centres across the US. It will look at the safety and effectiveness of a new, water-soluble formulation of liprotamase.

    • Age:

      28 Days to 17 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      7

    • Length of Participation:

      24 weeks

    Contact us about this clinical Trial >
  • Anti-InflammatoryCompleted with results Location: USA

    AquADEKs-2: Effects of an antioxidant-enriched multivitamin on inflammation and oxidative stress in people with CF , protocol number AquADECKs-IP-12

    This study took place at multiple care centres across the US. It looked at the effects on an anti-oxidant enriched multivitamin supplement on inflammation and oxidative stress in people with CF.

    • Age:

      10 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      40 to 100%

    • Number of Visits:

      4

    • Length of Participation:

      20 weeks

    Contact us about this clinical Trial >
  • Mucociliary ClearanceEnrolling Location: Multiple care centres across the US

    Cohorts 1 & 2 of a study to evaluate inhaled QBW276 in adults with CF , protocol number Novartis NCT0256X2201

    Cohorts 1 & 2 of a study to evaluate inhaled QBW276 in adults with CF

    • Age:

      18 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40-100%

    • Number of Visits:

      6

    • Length of Participation:

      14 Days

    Contact us about this clinical Trial >
  • Displaying results 81-90 (of 142)
     |<  <  5 - 6 - 7 - 8 - 9 - 10 - 11 - 12 - 13 - 14  >  >|